Clinical trial
Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced…
NCT00072631 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00072631 |
|---|---|
| Title | Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase II, Open-label, Intra-patient Dose-escalation Study of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed Prior Chemotherapy |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy |
| Intervention type | Drug |
| Interventions | Tarceva (Trademark) (erlotinib HCl, OSI-774) |
| Enrollment | 43 |
| Start date | Nov 5, 2003 |
| Primary completion | Mar 14, 2007 |
| Completion | Mar 14, 2007 |
| First posted | Nov 7, 2003 |
| Last update posted | Feb 8, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: